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Abstract
We investigated expression profiles and biological 
effects of the naked DNA vectors in the heart. To this  
end, naked DNA vector was injected into the apex  
of the beating rat heart after thorocotomy. When the  
expression of LacZ reporter was examined by  
reverse transcription-PCR and histochemical 
staining for β-galactosidase, LacZ expression was 
detected only in the heart, suggesting limited  
dissemination of the injected vector in vivo. Even  
within the heart, LacZ expression was limited to the  
injection area (apex). Similar observations were  
made with other transgenes such as VEGF and  
basic fibroblast growth factor (bFGF), where 77%  
and 69% of the total transgene exprssion were  
detected in the heart segments containing the apex. 
Although VEGF and bFGF expressions were de-
tected until 2 weeks after DNA injection, the highest 
levels of VEGF and bFGF were observed on day 5  
and day 1, respectively. The optimal doses of the  
vectors were 10 µg and 25 µg for the VEGF and bFGF 
vectors, respectively. Interestingly, injection of 
bFGF vector led to 50% increase in the level of 
endogenous murine VEGF expression. Consistent 
with this finding, the number of vessels that stained  
positive for α-smooth muscle actin was increased  
in the bFGF vector-injected heart. These results  
suggest that simple injection of naked DNA vector 
may be sufficient to induce significant angio -
genesis in the myocardium and that naked DNA 
gene therapy may be a feasible approach for the  
treatment of ischemic heart disease.
Keywords: angiogenesis; basic fibroblast growth fac-
tor; gene therapy; heart; myocardium; vascular endo-
thelial growth factor
Introduction
The number of patients suffering from ischemic heart 
disease (IHD) is growing rapidly these days (Jones 
et al., 1983; Mukherjee et al., 1999). Despite conti-
nued advances in the treatment of IHD, up to 15% of 
patients are not amenable to conventional therapies 
or receive incomplete revascularization (Wu et al., 
2004). For the treatment of such no-option patients, 
development of a novel therapeutic modality is 
urgently needed (Sellke et al., 2003; Ye et al., 2003). 
Recently, therapeutic angiogenesis that is based on 
exogenous administration of angiogenic growth fac-
tors has emerged as a promising strategy for the 
treatment of tissue ischemia (Lee et al., 2000b; Kim 
et al., 2004). The potential of therapeutic angiogene-
sis has been validated in various animal models of 
limb or myocardial ischemia and recently in patients 
treated with VEGF and bFGF (Banai et al., 1994; 
Harada et al., 1994; Kim et al., 1994; Unger et al., 
1994; Lazarous et al., 1996; Koh et al., 2002; 
Yamamoto et al., 2003; Hughes et al., 2004).
  Gene transfer can be an effective means to provide 
localized delivery of a high concentration of angio-
genic growth factors to the ischemic tissue. Among 
several gene delivery vectors that are currently used 
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to induce angiogenesis, naked DNA vectors provide 
the simplest means of expressing target genes (Ver-
ma et al., 1997; Lee et al., 2000b). When used alo-
ne, it avoids infectious agents and cumbersome 
production procedures that are often associated with 
viral or other gene transfer vectors (Sellke et al., 
2003). Importantly, the injected DNA vectors mostly 
remain episomal with greatly reduced risk for the 
integration into host chromosome. Also the naked 
DNA vectors essentially have no limit for the size of 
inserts and thus can accommodate larger inserts 
that can hardly be used effectively in other gene 
delivery systems (Heilmann et al., 2003). 
  The two dominant families of angiogenic factors 
that have been widely studied are FGF and VEGF 
(Rutanen et al., 2004; Wu et al., 2004). The thera-
peutic potential of these growth factors, either as 
protein or gene, has been confirmed in many pre- 
clinical studies (Carmeliet, 2000a; Isner et al., 2002; 
Simons et al., 2002; Kim et al., 2003; Wu et al., 
2004). VEGF gene therapy has been shown to in-
crease myocardial perfusion and function in coro-
nary artery diseases (Lee et al., 2000a; Isner et al., 
2002). Also beneficial long-term effects of FGF were 
reported recently (Carmeliet, 2000a; Lee et al., 2000a; 
Sellke et al., 2003). However, despite these diverse 
applications of VEGF and bFGF for ischemic heart 
diseases, comparative expression studies on the 
naked DNA vectors encoding VEGF and bFGF have 
been limited.
  In the present study, we evaluated cardiac expres-
sion profile of the naked DNA vectors encoding 
VEGF and bFGF for their therapeutic potential in 
ischemic heart disease. The time course of expre-
ssion, dose response, and spatial distributions were 
examined in a comparative manner. Also the in-
crease in vessel count was examined for their bio-
logical efficacy. Considering the fact that little atten-
tion has been paid to the behavior of the naked DNA 
vectors injected into the heart, our study provides 
important information pertinent to the development 
of novel angiogenic gene therapy for the no-option 
patients who are not treated by conventional meth-
ods (Ruel et al., 2003; Sellke et al., 2003).
Materials and Methods
Naked DNA vector
The pGT2-VEGF plasmid DNA vector was con-
structed by cloning the human VEGF165 cDNA into 
the eukaryotic expression vector, pGT2 whose back-
bone carries a prokaryotic replication origin (ColE1), 
a bacterial kanamycin resistance gene, and a 
eukaryotic expression cassette consisting of HCMV 
promoter, an adenovirus tripartite leader sequence, 
SV40 late poly A, and SV40 enhancer. The plasmid 
DNA was produced to clinical grade according to the 
proprietary process established at the Dong-A Pha-
rm. Co. (Korea). Briefly, E. coli (DH5 ) cells carrying 
the plasmid were grown in a kanamycin-containing 
medium in a 20 L fermentor. The fermentation broth 
was subjected to a series of purification steps in-
cluding alkaline lysis, PEG precipitation, anion ex-
change chromatography, and gel filtration chroma-
tography. The purified plasmid was dialyzed against 
a formulation buffer (Saline, pH 7.0).
Animal experiments
All animal experiments conform to the Guide for the 
Care and Use of Laboratory Animals published by 
the US National Institute of Health (NIH Publications 
No. 85-23, revised 1996). Male Sprague-Dawley 
(SD) rats weighing 300 grams were used for naked 
DNA injection. The rats were anesthetized with intra-
peritoneal injection of ketamine-xylazine (50 mg/kg 
and 2 mg/kg, respectively), heated in warm pad 
(37oC), intubated, and mechanically ventilated with 
room air. Under aseptic conditions, a thoracotomy 
was performed through the left fifth intercostal spa-
ce, and the heart was exposed. Cardiac injections 
were made directly into the apex of the left ventricle. 
Fifty microliter of DNA solution containing each 
plasmid was injected into the apical portion of the 
beating left ventricle, under direct visualization, using 
a 29-gauge needle. The DNA injection caused im-
mediate sub-epicardial edema, with the tissue color 
changing from red to pink. The chest was then 
closed and the animals allowed to recover for 
specific periods of time before sacrifice. Five to ten 
rats were used per each group.
Measurement of VEGF and bFGF
Rats were killed at the indicated time points following 
cardiac injection. After trimming away the atria, one 
fourth segment of the heart containing apex region 
(approximately 200 mg around the injection site) 
was excised, frozen by immersing in liquid nitrogen, 
and stored at -75oC until needed. The harvested 
heart was homogenized in 1 ml of ice-cold homo-
genization buffer (0.1 M Tris-HCl, pH 7.8 containing 
2 mM EDTA and 0.1% Triton X-100). Homogenates 
were centrifuged at 14,000 rpm for 10 min at 4oC. 
Supernatants were collected to measure the level of 
human VEGF, bFGF and mouse endogenous VEGF 
using Quantikine immunoassay kits (R&D systems, 
MN) according to the manufacturer’s protocols. Total 
protein concentration of the supernatant was also 
determined by Bradford assay (Bio-Rad, CA). The 
results were expressed as picograms of cytokine per 
milligram protein.
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RT-PCR
Total RNA was isolated from the heart tissues ac-
cording to the protocol of RNeasy minikit (Qiagen, 
CA) and the cDNA synthesized using the Super-
script First-Standard Synthesis system for RT-PCR 
(Invitrogen, CA, USA). The LacZ cDNA was ampli-
fied using the forward primer (5'-CTGCATAAACC-
GACTACACA-3') and the reverse primer (5'-TTTCA-
ATATTGGCTTCATCC-3'). The forward and reverse 
primers for GAPDH were 5'-CGTGGAAGGACTCAT-
GAC-3' and 5'-CAAATTCGTTGTCATACCAG-3', re-
spectively. 
Histological analysis
For general histological analysis, the heart sections 
were stained with hematoxylin and eosin (H & E). 
For immunostaining, the hearts were collected im-
mediately after sacrifice and embedded in OCT 
medium. The frozen sections (5 m thickness) were 
stained with von Willebrand factor (vWF) antibody 
(Dako, Carpinteria, CA) to count the number of 
capillaries. In addition, the frozen sections were 
stained with the monoclonal antibody against smoo-
th muscle -actin ( -SMA; clone 1A4, Dako, Carpin-
teria, CA) to count the number of mature vessels. 
Anti- -SMA antibodies were detected by VECTASTAIN 
Universal Quick Kit (Vector Laboratories, Burlin-
game, CA) according to the manufacturer’s instruc-
tions. Three sections having equal separation dis-
tance were examined per animal. The capillaries 
were counted and averaged from 10 representative 
fields at 400 × magnification.
LacZ staining
The heart tissue was rinsed three times in cold phos-
phate-buffered saline (PBS), embedded in OCT med-
ium, and quick frozen in liquid nitrogen. Cryostat sec-
tions (7 m) were air dried, rehydrated in PBS (pH 7.4) 
for 10min, and developed in a substrate solution [5 
mM K3Fe(CN)6, 5 mM K4Fe(CN)6, 2 mM MgCl2, 
0.01% sodium deoxycholate, 0.02% NP-40, 1 mg/ml 
X-gal] overnight at 37oC.
Statistical analysis
The data are expressed as mean ± SEM. One-way 
Figure 1. Analysis of biodistribution 
and safety of injected DNA. (A) 
Assessment of LacZ mRNA ex-
pression in different tissues after 
pGT2 naked DNA injection. Total 
RNA (1 g) isolated from the in-
dicated tissue at Day 5 was used 
for RT-PCR analysis. (B) Histoche-
mical staining for -galactosidase 
expression in the injected area 
(apex) of the heart. Ten microgram 
of pGT2-LacZ DNA was injected in-
to the rat heart followed by X-Gal 
staining at Day 5. -galactosidase 
expression was only shown in the 
apex of the heart. No acute organ 
toxicities were observed in the in-
jected rat. Original magnification, ×
400. (C) The hearts from each 
group were sectioned at 7 m thick-
ness and stained with H & E (×
200 magnification). Salient patho-
logical findings were not observed 
in the heart.
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analysis of variance followed by Bonferroni’s post 
hoc multiple comparison tests were used to evaluate 
statistical differences between the groups. A P value 
of less than 0.05 was considered statistically signi-
ficant. 
Results
LacZ transgene expression following cardiac
injection
To investigate transgene expression from the naked 
DNA vector in the heart, we injected 10 g of pGT2- 
LacZ vector into the rat myocardium and analyzed 
the LacZ expression by RT-PCR and LacZ staining 
(Figure 1) at day 5. The empty vector pGT2 served 
as a negative control for LacZ transgene. Following 
cardiac injection, other organs were also examined 
for the presence of unintended LacZ expression 
which would indicate dissemination of the vector. In 
RT-PCR analysis (Figure 1A), the band correspon-
ding to the LacZ mRNA was easily detected in the 
heart sample, whereas none were detected in sam-
ples from other organs or the empty vector-injected 
heart. This implies that LacZ expression from the 
pGT2-LacZ vector was restricted to the injected 
organ. When the heart tissues were subjected to 
immunohistochemical staining for -galactosidase 
expression (Figure 1B), LacZ-positive cells were 
identified as blue staining-cells near the injection 
area. The intense deep blue staining also suggested 
that the pGT2-LacZ vector drove high level expres-
sion of LacZ. No adverse effects were found along 
the needle track as determined by the H & E staining 
of the heart tissue (Figure 1C). 
Angiogenic gene expression from the naked DNA 
vector injected into the myocardium
Next, we examined angiogenic gene expression 
Figure 2. Spatial distribution of VEGF and bFGF expression. Five days after injection of the naked DNA into the apex of heart, the rats were sacrificed 
and the excised hearts were divided into four segments ranging from apex to base. Using ELISA, each segment was assayed for the expression of ei-
ther VEGF (A) or bFGF (B). The ELISA data was normalized against the amount of protein in the given tissue. The data are mean ± SEM (n = 5). The 
percentage of expression is also shown schematically on the right panel.
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from the naked DNA vector in the myocardium. To 
this end, cDNAs of the most widely studied growth 
factors, VEGF and bFGF, were inserted into the 
pGT2 vector and injected into the rat heart. Since 
localized expression pattern was observed in the 
case of LacZ transgene (Figure 1B), we again 
examined spatial distribution of each cytokine gene 
expression by quantifying the expression level of 
VEGF and bFGF along the heart axis from the base 
to the apex (Figure 2). At day 5, the isolated heart 
was cut into four pieces and each segment was 
homogenized and measured for the level of trans-
gene expression using ELISA. The amount of pro-
teins extracted from each segment was similar 
between the VEGF and bFGF. Consistent with the 
LacZ study, most of the VEGF and bFGF expression 
(77.1% and 66.8%, respectively) was restricted to 
the apex segment containing the injected region. 
These findings suggest that cardiac injection of the 
naked DNA vector can bring about significant local 
expression of therapeutic gene in the injected area 
and thus can be a feasible approach for the treat-
ment of heart diseases having local pathologic 
regions such as ischemic heart disease.
Dose response and time course of transgene
expression
To optimize gene expression from the cardiac-inject-
ed naked DNA vector, we examined dose response 
and time course of VEGF and bFGF gene ex-
pression. As shown in Figure 3A, the optimal dose 
for pGT2-VEGF was estimated at 10 g. Doses 
higher than 10 g did not lead to further increase, 
but rather resulted in a decrease of expression 
(Figure 3A). We have also examined the time course 
of VEGF gene expression after direct intramyo-
cardial injection of pGT2-VEGF (Figure 3B). The 
maximum level of VEGF expression was observed 
at day 5 with two different doses (10 g and 25 g) 
of pGT2-VEGF. Compared with the gradual increase 
in gene expression until day 5, rapid drop in VEGF 
expression was observed after day 5. This is in 
contrast to the bFGF case, where rapid increase in 
gene expression was followed by gradual decrease 
in bFGF expression (Figure 4B). Also, the optimal 
dose for bFGF expression was estimated to be 25 
g, which is higher than the optimal dose of VEGF. 
Overall, the tissue expression level of bFGF was 
approximately 3-fold higher than that achieved with 
VEGF. Also, compared with the short duration of 
VEGF expression, bFGF expression persisted even 
after day 14. These differences in expression profile 
between VEGF and bFGF may be explained in part 
by the short-half and secretory nature of VEGF 
(Ferrara et al., 1992).
Vascularity following angiogenic gene expression
Next, we examined angiogenic response in the 
myocardium following cardiac injection of pGT2- 
LacZ, pGT2-VEGF, and pGT2-bFGF. The number of 
capillaries was counted from the heart sections 
stained with vWF, which was then normalized by the 
number of myocytes. As shown in Figure 5A, VEGF 
or bFGF group did not result in a significant increase 
Figure 3. Dose response and time course of the VEGF expression from the naked DNA vector in the rat heart. (A) Dose response of VEGF expression. 
Different amounts of pGT2-VEGF DNA were injected into the apex region of the rat heart. Five days after DNA injection, the heart segment containing 
injected area (apex) was excised and the level of VEGF protein determined. Normal saline solution was used as a negative control. Values are given as 
mean ± SEM (n=20). *** P ＜ 0.001 vs. other groups. (B) Time course of VEGF expression. Following injection of 10 g (circle) or 25 g (square) of 
pGT2-VEGF DNA, the heart segment containing injected area (apex) was excised and assayed for VEGF using ELISA at each time point. Values are 
given as mean ± SEM (n = 10 for each dose). *** P ＜ 0.001, * P ＜ 0.05 compared to Day 1.
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in capillary density compared with control (LacZ) 
group. However, when the sections were stained for 
the presence of smooth muscle -actin ( -SMA) 
marker that is expressed in both pericytes and 
smooth muscle cells of mature blood vessels, the 
FGF and VEGF group had significantly increased 
the number of -SMA-positive vessels than the 
control (LacZ) group (Figure 5B). Statistically sig-
nificant differences were not found between the 
VEGF and bFGF groups.
Figure 5. Increased vessel formation following the naked DNA vector injection. (A) Capillary density of the rat myocardium evaluated in frozen section 
stained with vWF. Capillary/muscle fiber ratio refers to the number of capillaries divided by the number of myofibers. Original magnification, × 400. (B) 
Arteriole density evaluated in longitudinal section of the myocardium stained with the antibody against -SMA. Values are given as mean ± SEM (n =
5). *** P ＜ 0.001, ** P ＜ 0.01 compared to LacZ group. ns, not significant.
Figure 4. Dose response and time course of the bFGF expression from the naked DNA vector in the rat heart. (A) Different amounts of pGT2-bFGF 
DNA were injected into the rat heart. Five days after DNA injection, the heart segment containing injected area (apex) was excised and the level of 
bFGF protein determined. Normal saline was used as a negative control (0 g). Values are given as mean ± SEM (n = 8-9). *** P ＜ 0.001 compared 
to control (0 g). * P ＜ 0.05. ns; not significant. (B) Following injection of DNA (25 g) into the rat heart, the heart segment containing injected area 
(apex) was excised and assayed for the level of bFGF using ELISA at each time point. Values are given as mean ± SEM (n=8-9). *** P ＜ 0.001 com-
pared to Day 7 and Day 14. * P ＜ 0.05 compared to Day 5. ns, not significant.
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bFGF induces endogenous VEGF expression
Since it was previously reported that bFGF can 
induce expression of VEGF (Stavri et al., 1995; Ra-
bie et al., 2004), we investigated whether the similar 
effect can be found in the rat myocardium. When the 
rat hearts were injected with pGT2-LacZ, pGT2- 
VEGF, and pGT2-bFGF and analyzed for the level of 
endogenous murine VEGF level, significant increase 
in the level of murine VEGF was observed in the 
group injected with pGT2-bFGF (Figure 6). This 
indicates that overexpression of human bFGF can 
upregulate the expression of endogenous murine 
VEGF, whereas overexpression of VEGF or control 
LacZ gene has little effect. There was no further 
increase in murine VEGF level with higher dose of 
pGT2-bFGF (25 g).
Discussion
This study was carried out as part of the pre-clinical 
evaluation of the naked DNA vectors encoding two 
typical angiogenic genes, VEGF and bFGF. The 
pGT2 DNA vectors were developed for high level 
expression of therapeutic gene and our preliminary 
study indicated that it drove high level expression of 
target gene in the muscle tissues both in vitro and in 
vivo (unpublished data). Considering the fact that 
little is known about the behavior of naked DNA 
vectors injected into the myocardium, our study 
provides much-needed information with regard to 
the spatial and temporal characteristics of transgene 
expression in the heart. Also, the optimal dose and 
time point of angiogenic gene expression deter-
mined in myocardial tissue as well as the evidence 
of increased vascularity following VEGF and bFGF 
vector injection should prove very useful for the 
researchers in the field. Since less invasive per-
cutaneous catheterization can be easily applied for 
intramyocardial injection of naked DNA, the results 
of our study has an implication for the development 
of novel angiogenic gene therapy for ischemic heart 
diseases. 
  Naked DNA vector may be an effective strategy for 
therapeutic angiogenesis in ischemic myocardium 
(Tsurumi et al., 1996; Tio et al., 1999; Vale et al., 
2001; Rutanen et al., 2004). Despite the instability 
and short duration of the injected DNA, the increa-
sed vascularity following pGT2-VEGF and pGT2- 
bFGF implies that local injection of naked DNA 
vector is sufficient for effective cellular uptake and 
biological effects in the myocardium. This result is 
supported by other studies where administration of 
the VEGF DNA vector facilitated local angiogenesis 
and the reperfusion of the ischemic tissues (Mack 
CA et al., 1998; Rutanen J et al., 2004). Regarding 
the utility of naked DNA vector, the use of non-viral 
vectors is disproportionately high in cardiovascular 
field, which is in contrast to the widespread appli-
cation of viral vectors in other areas. Approximately 
half of the gene therapy trials in cardiovascular field 
used naked DNA vectors (Isner, 2002). This can be 
explained in part by the relatively high transfection 
efficiency of naked DNA in the myocardium (Lee et 
al., 2000b; Isner et al., 2001; Heilmann et al., 2003). 
Moreover, the simplicity of DNA vector may have 
been an important factor in the choice of vector. 
Nevertheless, the use of viral vectors is still a good 
option to increase the magnitude and duration of 
gene expression at the expense of decreased safety.
One of the concerns associated with myocardial 
injection of naked DNA vector is its expression in 
unintended organs. Since complete retention of the 
vector at the injection area is unlikely to occur even 
under the most carefully controlled conditions, dis-
semination of injected DNA and its expression in 
various organs need to be monitored closely. In the 
present study, however, expression of the injected 
DNA was not detected in other organs by RT-PCR 
assays (Figure 1). Also inadvertent dissemination of 
DNA into other tissues via the bloodstream was not 
detected at 2 hr after the intramyocardial admini-
stration in most organs (data not shown). This may 
be in part due to a rapid degradation of the plasmid 
DNA by the plasma deoxyribonuclease (DNase) and 
the enzymes in other body compartments such as 
the liver (Acharya et al., 2004). Considering the high 
degradation rate of the plasmid DNA in vivo and the 
fact that the dose (25 g DNA) used in this study is 
Figure 6. bFGF upregulates endogenous expression of mouse VEGF. 
pGT2-VEGF (10 g) or pGT2-bFGF (10 g or 25 g) DNA was injected 
into the apex region of the rat heart. Five days after DNA injection, the 
injected area was excised and the level of mouse VEGF protein 
determined. Induction of endogenous VEGF is noted in bFGF group. 
Values are given as mean ± SEM (n = 8-9 for each dose). * P ＜ 0.05, 
*** P ＜ 0.001 compared to LacZ group. ns; not significant.
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merely several-fold higher (per bodyweight) than that 
expected in clinical applications, it is highly unlikely 
that significant amount of plasmid DNA will reach the 
non-target organs via blood circulation and persist in 
these organs in actual clinical situations. The risk of 
insertional mutagenesis or germ line transmission 
also appears to be negligible as the genomic inte-
gration in the injected tissue or the mRNA production 
in the testis was not detected by PCR or RT-PCR 
(data not shown). These observations all together 
suggest that local injection of naked DNA vector 
may be a safe procedure with little concern for the 
adverse effects. 
  With regard to the safety issues related to forced 
upregulation of angiogenic factors, systemic admini-
stration of VEGF can induce hypotension and car-
ries theoretic risk of inducing occult tumors and 
inappropriate angiogenesis in the retina and the 
synovium. However, the relatively low expression 
level that is achieved using naked DNA vector is 
expected to compromise such effects. Compared 
with our previous study using pCN-VEGF121 (Jeong 
et al., 2002), the present study reveals different 
VEGF expression pattern in terms of dose response 
and time course of expression, which could be 
explained in part by the different vector, VEGF 
isoform (VEGF165), and the experimental methods 
used. In addition, more animals were used in the 
present study to provide extensive comparisons. As 
such, the results of the present study would help to 
increase our understanding of the behavior of naked 
DNA vectors encoding angiogenic genes in the 
myocardium.
  One of the reasons for the use of nonischemic 
heart in this study was that collateral growth begins 
in normoxic areas. On the other hand, we can 
minimize confounding effects of ischemic tissues, in 
which there is an upregulation of various endo-
genous growth factors and their receptors (Rutanen 
et al., 2004). When this latter point is acknowledged, 
upregulation of endogenous VEGF following bFGF 
vector injection in the normoxic heart (Figure 6) 
implies that there may be even stronger induction of 
VEGF in the ischemic heart. This upregulated ex-
pression of endogenous VEGFs may act in concert 
with the delivered bFGF, creating enhanced respon-
se in the myocardium. Indeed, the number of mature 
vessels was larger in bFGF-treated group than in 
VEGF-treated group (Figure 5), consistent with our 
speculation. In other aspect, hemangioma formation 
and vascular leakage that may be seen with VEGF 
gene therapy were not observed with FGF-encoding 
vectors at doses that allow for biological response 
(Lopez et al., 1997; Carmeliet, 2000b; Lee et al., 
2000a). Therefore, it appears that administration of 
bFGF may be advantageous over that of VEGF in 
terms of safety as well as efficacy. However, more 
study would be required to elaborate on this point. 
  In conclusion, we provide evidence that naked 
DNA vectors are capable of delivering angiogenic 
genes safely to myocardium and that the delivered 
VEGF and bFGF genes are capable of inducing 
significant angiogenesis in vivo in nonischemic heart. 
Since it is reasonable to expect that this naked DNA 
strategy can be used clinically as an adjunct or 
alternative to conventional revascularization thera-
pies to promote collateral vessel formation, our re-
sults should have implications for many current and 
future angiogenic gene therapy trials.
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